Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2012

Aug 8, 2012

151_ip_2012-08-08_cf5cf5c6-3b85-4372-be5e-002bb81b1a69.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Innovation Pro b fita le n & G or wth

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this presentation. Such statements are neither promises nor gua subject to a variety of risks and uncert which are beyond our control control, and wh ntation containsolve a number ofoking statements nt of Evotec as offorward-looking arantees, but are tainties, many of hich couldcause

actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim an obligation or ndertaking to release p blicl any undertakingpublicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Welcome to Evoteec!

Your management team

Agenda

•Highlights H1 2012

  • • Action Plan 2016 – Innovation Efficiency
  • EVT Execute
  • EVT Integrate
  • EVT Innovate
  • • Financial performance & growth outlook

Building innovatio on on the back of profitable growth

Strongest H1 in company h history

Strong profitable g growth, different revenue mix

Key figures overview – Sta atus H1 2012 vs. H1 2011

All elements of guidance comfortably confirmed

Guidance overview

$\ln \epsilon$ m Guidance 2012 FY 2011
Revenues $88 - 90$ 80.1
Operating income 1) Improved over 2011 5.2
Innovation investments
(R&D Expenses)		 Approx. 10 8.4
Capex investments > 10 8.1
Liquidity at period end Above 60 62.4

Agenda

  • •Highlights H1 2012
  • • Action Plan 2016 – Innovation Efficiency
  • EVT Execute
  • EVT Integrate
  • EVT Innovate
  • • Financial performance & growth outlook

The offering for Innovation Efficiency

Action Plan 2016

Strong growth in h high quality services

Comprehensive Drug Disc covery Platform – "EVO Apps"

Highest quality outsourcing services

EVT Execute - Major milestones and actions for H2

Improvement of compound management business

Completion of commercial offering with 4-Antibody

Expansion of EVT Execute capabilities strengthen risk shared initiatives

Good p g ro ress in highlighted by BI-m on-gg y oin discovery alliances milestone

EVT Integrate - Business m model

Building an even stronger portfolio of upside opportunities

EVT Integrate - Major milestones and actions for H2

Expansion of portfolio with at least one more strategic multi-target alliance

Further milestone achievements in ongoing alliances

Expansion of customer reach to even more biotech, mid-sized and large pharma customers

A strategic pharma financial riskaportfolio without

EVT Innovate

I
d
i
i
t
n
c
a
o
n		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
i
l
t
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
)
1
D
i
b
t
a
e
e
s		 P
P
h
h
I
I
I
I
I
I
l
l
2
a
s
e
c
o
s
s
e
l
i
t
t
o
c
o
m
p
e
o
n		 F
i
l
P
h
I
I
I
d
t
n
a
a
s
e
a
a		 A
€
i
i
l
l
l
i
4
0
t
t
t
p
p
r
o
x.
m
m
m
e
e
s
s
o
o
n
n
e
e
s
s,
r
o
y
a
e
s
;
i
l
k
€
5
0
0
t
t
t
p
o
e
n
a
m
a
r
e
a
p
p
r
o
x.
m
A
l
h
i
z
e
m
e
r
s
)
2
D
i
s
e
a
s
e		 P
h
I
I
a
s
e		 P
h
I
I
b
i
i
i
i
t
t
a
s
e
n
a
o
n		 \$
A
i
l
8
2
0
t
p
p
r
o
x.
m
m
e
s
o
n
e
s,
\$
l
i
i
l
k
b
3–
5
t
t
t
t
r
o
y
a
e
s
;
p
o
e
n
a
m
a
r
e
n
T
i
t
t
t
t
r
e
a
m
e
n
r
e
s
s
a
n
3
)
d
i
e
p
r
e
s
s
o
n		 O
p
e
n		 P
h
I
I
a
s
e		 N
i
t
e
p
a
r
n
e
r
n
g
w		 O
p
e
n
)
4
I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 P
h
I
I
b
t
t
a
s
e
s
a
r		 M
i
l
l
i
t
t
e
s
o
n
e
s,
r
o
y
a
e
s
)
5
f
I
l
i
t
n
a
m
m
a
o
n		 P
h
I
/
I
I
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 A
€
6
0
i
l
l
i
t
t
p
p
r
o
x.
m
m
e
s
o
n
e
s,
r
o
y
a
e
s
I
f
l
i
i
t
n
a
m
m
a
o
n
n
6
)
i
l
h
l
h
t
a
n
m
a
e
a		 /
P
h
I
I
I
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 M
M
i
i
l
l
l
i
t
t
t
e
e
s
s
o
o
n
n
e
e
s,
s
r
o
a
e
s
y
D
i
b
t
a
e
e
s		 J
/
a
n
s
s
e
n		 R
h
e
s
e
a
r
c		 P
l
i
i
l
r
e-
c
n
c
a		 \$
f
U
8
h
t
t
p
r
o
n
m
r
e
s
e
a
r
c
p
a
y
m
e
n
u
p
;
;
\$
3
0
0
i
l
d
t
t
t
o
m
m
e
s
o
n
e
s
p
e
r
p
r
o
c
u
;
l
i
t
r
o
a
e
s
y
)
7
O
h
t
e
r
s		 O
p
e
n		 P
l
i
i
l
r
e-
c
n
c
a		 P
i
t
a
r
n
e
r
n
g		 O
p
e
n
C
U
R
E
X
I
i
i
i
t
t
n
a
e
s
v		 O
p
e
n		 P
P
l
l
i
i
i
i
l
l
r
r
e
e-
c
c
n
n
c
c
a
a		 I
i
i
i
t
t
n
a
o
n		 O
p
e
n

1) DiaPep277 is being developed by Andromeda Biotech L Ltd and has been partnered with TEVA Pharmaceuticals Industries Ltd

2) EVT 302 (Mao-B ) ; 3)EVT 101/103 series; 4) Chinese r rights only; safety and Phase IIb study planned starting 2012 (EVT 201)

5) EVT 401 (P2X7) ; 6)Animal Health (undisclosed) (EVT 401 (P2X7) ); 7) EVT 501 (H3), P2X3, …

Building up a portf folio of high-value assets

Update on assets

E
V
T
3
0
2		 E
V
T
4
0
1
D
l
l
i
b
i
l
i
i
d
l
l
t,
t
t
t
e
v
e
o
p
m
e
n
r
e
g
u
a
o
r
y
r
e
s
p
o
n
s
e
s
a
n
a
c
o
s
s
•
h
b
f
d
R
h
t
t
a
v
e
e
e
n
r
a
n
s
e
r
r
e
o
o
c
e
D
l
f
i
l
i
l
l
d
l
t
t
t
t
t
t
e
e
o
p
m
e
n
p
r
o
e
c
a
n
p
p
o
e
n
a
a
r
g
g
e
s
a
n
a
o
n
e
v
y
y
•
l
i
i
b
i
i
i
A
D
t
t
t
t
t
a
p
p
c
a
o
n
o
r
c
o
m
n
a
o
n
r
e
a
m
e
n
s
n
L
P
h
I
I
b
i
l
i
i
f
i
H
2
2
0
1
2
t
t
t
t
a
r
g
e
a
s
e
r
a
n
p
r
e
p
a
r
a
o
n
o
r
s
a
r
n
•		 E
l
i
l
i
f
C
h
i
l
d
C
b
t
t
x
c
u
s
v
e
c
e
n
c
e
o
r
n
a
o
n
y
g
r
a
n
e
o
o
n
a
•
P
h
f
h
l
C
h
i
h
i
t
t
a
r
m
a
o
n
e
o
e
a
r
g
e
s
n
e
s
e
p
a
r
m
a
c
o
m
p
a
n
e
s
–
S
f
f
l
l
€
6
0
i
l
d
i
d
t,
t
t
t
m
a
u
u
p
p
r
r
o
o
n
n
a
a
p
p
p
p
r
r
o
o
x
x.
m
m
e
s
o
n
e
s
a
n
e
r
e
•
d
b
l
d
i
i
l
i
f
i
f
l
i
d
i
t
t
t
o
u
e-
g
r
o
y
a
e
s
o
r
n
a
m
m
a
o
n
s
e
a
s
e
s
O
f
i
i
l
i
A
i
l
H
l
h,
i
t
t
t
n
g
o
n
g
r
a
s
n
n
m
a
e
a
p
a
r
n
e
r
n
g
p
r
o
c
e
s
s
o
r
•
h
i
u
m
a
n
s
o
n
g
o
n
g
/
E
V
T
1
0
1
1
0
3		 /
O
h
l
i
i
l
l
i
i
l
t
e
r
c
n
c
a
p
r
e
-c
n
c
a
p
r
o
g
r
a
m
m
e
s

Multip gy le highly inn modifying approac novative, p y otentially disease ches

Evotec's unique diabetes f franchise

  • Larg undgest collaboration in beta cell regeneration, isclosed targets identified and validated by Harvard / Evotec
  • Stat tus discovery

rolledd over into pharma

"Win – Win – Win" situation

C
B
t
r
e
e
a
u
t
e
r
m
s		 \$
\$
U
f
i
l
i
l
d
(
l
i
i
l,
8
2
0
0
3
0
0
t
t
t
t
t
t
p
r
o
n
m
p
o
e
n
a
m
e
s
o
n
n
e
s
p
o
m
p
e
r
p
r
o
c
p
r
e
-c
n
c
a
u
u
•
-
,
l
i
i
l,
l
i
l
)
t
c
n
c
a
r
e
g
a
o
r
c
o
m
m
e
r
c
a
u
y,
S
i
i
f
i
l
i
t
t
g
n
c
a
n
r
o
y
a
e
s
•
R
h
t
e
s
e
a
r
c
p
a
y
m
e
n
s
•
/
/
W
i
W
i
W
i
n
n
n
l
l
i
a
a
n
c
e		 J
A
i
f
i
i
l
b
i
l
i
d
l
l
l
l
d
i
d
t-
a
n
s
s
e
n
c
c
e
s
s
n
g
r
s
n
-c
a
s
s
s
o
o
g
c
s
a
n
s
m
a
m
o
e
c
e
s
c
o
e
r
a
n
:
u
v
y
•
d
l
l
f
d
i
i
d
i
b
t
t
t
t
e
e
o
p
m
e
n
p
a
o
r
m
a
n
e
p
e
e
r
s
e
n
a
e
e
s
v
x
E
E
d
i
l
d
h
i
i
b
l
l
i
h
i
h
l
i
i
b
i
d
t
t
t
t
t
t
t
o
e
c
v
:
x
p
a
n
n
g
e
a
e
r
s
p
n
e
a
c
e
r
e
g
e
n
e
r
a
o
n
g
y
s
s
y
y
s
s
e
e
m
m
a
a
c
c
u
n
a
s
e
•
–
,
d
h
i
h
b
l
l
l
i
i
t
t
t
a
n
c
o
m
p
r
e
e
n
s
e
a
p
p
r
o
a
c
o
o
e
a
c
e
r
e
p
c
a
o
n
v
f
H
d
A
l
i
d
l
i
i
i
i
h
b
i
i
l
i
d
t
t
t
t
a
r
v
a
r
c
c
e
e
r
a
n
g
e
v
e
o
p
m
m
e
n
o
n
n
o
v
a
v
e
s
c
e
n
c
e
w
g
c
o
m
m
e
r
c
a
u
p
s
e
:
•
S
i
i
t
t
t
a
r
n
g
p
o
n
f
i
i
t
o
r
n
n
o
a
o
n
v
f
f
i
i
d
e
c
e
n
c
a
n
y
l
t
e
e
r
n
a
x
i
i
t
n
n
o
a
o
n
v		 f
P
h
i
d
i
h
h
&
k
h
d
l
t
t
t
t
t
t
t
a
r
m
a
n
u
s
r
y
a
p
p
r
e
c
a
e
s
e
e
a
p
p
r
o
a
c
s
e
e
m
s
e
e
n
o
e
n
e
r
e
s
e
y
p
e
o
e
a
s
•
O
i
l
l
i
l
f
d
i
l
b
i
h
i
d
t
t
t
t
t
t
t
t
t
t
t
p
m
a
r
a
n
s
a
o
n
a
s
r
a
e
g
o
o
r
a
c
a
e
m
a
o
r
e
a
r
o
e
c
e
a
s
a
s
a
a
r
r
g
g
e
e
s
s
g
e
y
y
•
i
d
i
l
h
d
i
f
t
t
t
m
m
e
a
e
o
n
p
a
r
m
a
g
r
a
e
n
n
r
a
s
r
c
r
e
s
y
u
u

Building a Cure X pipeline

High unmet medical need and paucity of disease modifying targets…

C
B
t
u
r
e
e
a		 S
d
l
l
b
i
i
h
H
d
U
i
i
i
M
h
2
0
1
1
t
t
t
t
t
a
r
e
c
o
a
o
r
a
o
n
w
a
r
v
a
r
n
v
e
r
s
y
n
a
r
c
•
C
P
d
B
i
h
h
J
i
J
l
2
0
1
2
t
t
t
a
r
n
e
r
e
r
e
e
a
a
n
s
s
e
n
n
u
w
u
y
•
S
f
i
i
i
h
i
l
l
i
t
t
t
t
g
n
c
a
n
r
e
s
e
a
r
c
p
a
m
e
n
s
m
e
s
o
n
e
s
r
o
a
e
s
y
y
•
,
,
C
N
h
u
r
e
e
p
r
o
n		 S
d
l
l
b
i
i
h
H
d
U
i
i
i
F
b
2
0
1
2
t
t
t
t
t
a
r
e
c
o
a
o
r
a
o
n
w
a
r
v
a
r
n
v
e
r
s
y
n
e
r
u
a
r
y
•
H
i
h
l
d
i
i
i
d
i
d
&
d
t
t
t
t
t
g
p
r
o
c
e
n
g
e
n
e
e
r
a
n
g
c
a
n
a
e
a
r
g
e
s
c
o
m
p
o
n
s
y
u
v
u
•
C
N
u
r
e
e
u
r
o
n		 C
h
f
i
l
j
t
t
t
o
n
c
e
p
p
a
s
e
o
r
n
e
r
n
n
a
p
r
o
e
c
s
•
E
l
i
i
l
l
l
b
b
i
i
i
t
t
t
t
t
p
o
r
n
g
p
o
e
n
a
c
o
a
o
r
a
o
n
o
p
p
o
r
n
e
s
x
u
•
C
H
t
u
r
e
e
a
r		 C
h
f
i
l
j
t
t
t
o
n
c
e
p
p
a
s
e
o
r
n
e
r
n
n
a
p
r
o
e
c
s
•
E
l
i
i
l
l
l
b
b
i
i
i
t
t
t
t
t
p
o
r
n
g
p
o
e
n
a
c
o
a
o
r
a
o
n
o
p
p
o
r
n
e
s
x
u
•

First-in-class innowith focus in CNS, ovation, oncology and metabolics

EVT Innovation – Major m milestones and actions for H2

Agenda

  • · Highlights H1 2012
  • Action Plan 2016 Innovation Efficiency
  • EVT Execute
  • EVT Integrate
  • EVT Innovate

• Financial performance & growth outlook

$Ar9r331$

Strong profitable g growth

H1 2012: Condensed consoolidated statement of operations

i
€
n
m
H
1
2
0
1
1		 H
1
2
0
1
2		 %
2
0
1
1
s
v
R
e
v
e
n
u
e
s		 3
3
4		 4
2
0		 2
6
%
+
G
i
r
o
s
s
m
a
r
g
n		 4
3
3
%		 5
3
2
%
R
&
D
e
p
e
n
s
e
s
x
•		 4
7		 3
9		 1
6
%
-
S
G
&
A
e
x
p
e
n
s
e
s
•		 6
7		 8
0		 6
%
+
A
i
i
t
t
m
o
r
s
a
o
n
•		 0
5		 )
1
1
2
O
h
(
i
)
t
t
e
r
o
p
n
c
o
m
e
e
p
e
n
s
e
s
n
e
x
•		 0
7		 2
)
0
3
O
i
i
t
p
e
r
a
n
g
n
c
o
m
e		 0
9		 1
3		 4
5
%
+
i
N
t
e
n
c
o
m
e		 0
8		 1
7		 1
1
5
%
+

20 1) Mainly amortisation for Evotec San Francisco custom mer list

2) Including expenses for planned underutilisation from (earn-out) for Evotec Goettingen (€ 0.3m) and Evotec m parallel rental in Hamburg (€ 1.1m) and fair value adjustments in the context of the contingent consideration c San Francisco (€ -1.0m)

Operating and net income clearly improved

Q2 2012: Condensed cons olidation statement of operations

i
€
n
m
Q
2
2
0
1
1		 Q
2
2
0
1
2		 %
2
0
1
1
v
s
R
e
e
n
e
s
v
u		 1
8
3		 2
1
9		 2
0
%
+
G
i
r
o
s
s
m
a
r
g
n		 4
6
5
%		 3
%
7
7
R
&
D
e
x
p
e
n
s
e
s
•		 2
4		 2
0		 1
4
%
-
S
G
&
A
e
p
e
n
s
e
s
x
•		 3
8		 3
6		 %
5
-
A
i
i
t
t
m
o
r
s
a
o
n
•		 0
3		 )
1
0
7
O
(
)
h
i
t
t
e
r
o
p
n
c
o
m
e
e
x
p
e
n
s
e
s
n
e
•		 0
4		 )
2
(
)
0
7
i
i
O
t
p
e
r
a
n
g
n
c
o
m
e		 1
7		 2
6		 5
1
%
+
N
i
t
e
n
c
o
m
e		 1
2		 3
7		 2
1
1
%
+

2) Includes expenses for planned underutilisation from parallel rental in Hamburg (€ 0.5m) and

fair value adjustment in the context of the contingent consideration (earn-out) for Evotec San Francisco (€ -1.0m)

21 1) Mainly amortisation for Evotec San Francisco custom mer list

Gross margins ref businesses and caflect investments in new apacities

H1 2012: Revenues & gros ss margins

in € m

Positive trend in ooperating and net result continued

H1 2012: Results

in € m

Focused R&D investments for long term growth

H1 2012: R&D and SG&A

in $\notin$ m

Liq yp uidity expected with guidance (> € d to increase in H2 in accordance 60 m)

H1 2012: Condensed consoolidated statement of cash flows

Liquidity in € m

1
)
H
1
2
0
1
1		 1
)
H
1
2
0
1
2
(
)
N
h
i
d
d
b
d
i
t
e
c
a
s
p
r
o
v
e
y
u
s
e
n		 •
O
i
i
i
i
t
t
t
p
e
r
a
n
g
a
c
e
s
v
•		 3
3
6		 3
4
-		 •
I
i
i
i
i
t
t
t
n
e
s
n
g
a
c
e
s
v
v
•		 1
1
-		 0
9
-
F
i
i
i
i
i
t
t
n
a
n
c
n
g
a
c
e
s
v
•		 0
0
4
-		 2
1
E
h
d
i
f
f
t
c
a
n
g
e
r
a
e
e
r
e
n
c
e
x		 0
0
8		 1
4
C
h
d
h
i
l
d
f
i
d
t
t
a
s
a
n
c
a
s
e
q
u
v
a
e
n
s
a
e
n
o
p
e
r
o		 2
4
4
1		 1
6
9		 •
I
t
t
+
n
v
e
s
m
e
n
s		 3
2
2
4		 3
6
5
i
i
i
f
i
L
d
d
d
t
t
q
u
y
a
e
n
o
p
e
r
o
=		 5
6
6
5		 )
2
5
3
4		 •
f
L
i
i
d
i
b
i
i
i
d
t
t
q
u
y
a
e
g
n
n
n
g
o
p
e
r
o		 0
0
4
7		 6
2
4		 •
N
i
/
d
i
l
i
i
d
i
t
t
e
n
c
r
e
a
s
e
e
c
r
e
a
s
e
n
q
u
y		 1
3
3
9
-		 9
0
-
  • • Cash generative operating result offset by:
  • • Increase in working capital of g p € 9.0 m due to increased revenues, outstanding milestone and earn-outs
  • Includes significant Capex investments of € 51m 5.1 m
  • • Includes investment in 4-Antibody of € 2.0 m
  • • Financed by reduction in investments

Strong news flow to come

Outlook and next steps for r 2012 ff

Key milestones for 2012

E
V
T
E
1
t
x
e
c
u
e		 D
b
l
d
i
i
h
2
0
1
2
2
0
1
6
t
t
o
u
e
g
r
e
v
e
n
u
e
g
r
o
o
w
•
–
E
i
f
i
i
l
l
i
t
p
a
n
s
o
n
s
c
c
e
s
s
o
e
s
n
g
a
a
n
c
e
s
x
u
x
x
•
S
f
i
i
i
l
d
l
i
h
j
h
t
t
t
g
n
c
a
n
o
n
g
e
r
m
e
a
a
s
m
a
o
r
p
a
r
m
a
w
•
-
E
V
T
I
t
t
2
n
e
g
r
a
e		 /
/
A
l
i
i
i
i
f
f
i
i
i
i
d
d
h
h
l
l
d
d
i
i
l
l
i
2
2
t
t
t
t
t
t
t
t
t
t
e
a
s
s
g
n
c
a
n
n
e
n
e
g
r
a
e
e
c
n
o
o
g
s
e
a
s
e
a
a
n
c
e
s
w
w
y
•
D
l
i
i
i
f
i
d
l
d
l
i
i
l
/
l
i
i
l
i
l
t
t
t
e
e
r
s
g
n
c
a
n
a
n
a
a
c
c
e
e
r
a
e
p
r
e
c
n
c
a
c
n
c
a
m
e
s
o
n
e
s
v
•
S
f
h
i
l
i
i
i
i
t
t
t
o
w
o
p
e
r
a
o
n
a
s
y
n
e
r
g
g
e
s
o
r
e
c
e
n
a
c
q
u
s
o
n
s
•
E
V
T
I
t
3
n
n
o
a
e
v		 A
l
i
d
l
f
l
1
t
t
t
t
t
e
a
s
s
r
a
e
g
c
e
a
o
r
e
a
r
a
s
s
e
s
y
•
(
(
C
)
E
i
i
i
d
X
t
e
e
n
n
m
o
r
e
n
n
o
a
o
n
p
s
e
g
s
e
e
g
r
e
v
v
v
u
u
•
,
…
P
h
I
I
I
d
i
D
i
P
2
d
P
h
I
I
b
i
h
i
d
7
7
t
t
t
t
t
a
s
e
a
a
n
a
e
p
p
a
n
a
s
e
s
a
r
w
n
p
r
o
u
c
•
d
l
h
i
t
t
e
v
e
o
p
m
e
n
p
a
r
n
e
r
s
p
p
s

Building innovative drug discovery alliances

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Regulatory Filings 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Regulatory Filings 2026
May 5
View all filings →